Navigation Links
SyntheMed Announces New Management Appointments
Date:10/2/2008

ISELIN, N.J., Oct. 2 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD) announced today that Richard L. Franklin, MD, the company's Chairman, has assumed the newly-created position of Executive Chairman and Gere S. diZerega, MD, one of the company's clinical advisors, has assumed the newly-created position of Medical Director. In these consultancy roles, Dr. Franklin will be primarily involved with strategic planning, external communications and Board leadership whereas Dr. diZerega will focus on clinical and regulatory strategy and product planning. Robert P. Hickey, the company's President & CEO stated, "We are very fortunate that Rick and Gere have agreed to expand their involvement with our company and we look forward to benefiting from their experience and expertise."

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products and other surgical implants based on its proprietary bioresorbable polymer technology. The company is developing a portfolio of anti-adhesion products lead by REPEL-CV(R) Adhesion Barrier, an anti-adhesion product intended for use in open heart surgical procedures. REPEL-CV is currently marketed internationally and is awaiting FDA approval to market in the United States.

Statements in this press release that are not statements of historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed Completes $4.0 Million Equity Placement
2. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
3. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
4. SyntheMed Files Universal Shelf Registration
5. SyntheMed to Present at the Acumen BioFin Conference
6. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
7. Alba Therapeutics Corporation Announces Promotions
8. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
9. 23andMe Announces Breast Cancer Initiative
10. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
11. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions ... in the Aragon Research Globe™ for Corporate Learning, 2017. , Aragon Research defines ... market demand, and effectively perform against those strategies. NetDimensions’ ranking as a Leader ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... for advanced technology applications, has announced a facility expansion to accommodate its rapid ... square feet of new workspace and renovation of the existing areas. The expansion ...
(Date:5/23/2017)... ... ... Cambridge Semantics , the leading provider of Big Data management and analytics ... in Boston May 23-25 with a featured speaker and solution demos of its ... also a finalist for the Best of Show award. , James LaPointe, Managing Director ...
(Date:5/22/2017)... ... May 22, 2017 , ... Baltimore biotech firm, PathSensors, ... Biohealth community in developing and issuing recommendations to grow Maryland's biohealth industry and ... by 2023. , The recommendations are contained in a report ...
Breaking Biology Technology:
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
Breaking Biology News(10 mins):